MX2010001094A - Trazodona y hidrocloruro de trazodona en forma purificada. - Google Patents

Trazodona y hidrocloruro de trazodona en forma purificada.

Info

Publication number
MX2010001094A
MX2010001094A MX2010001094A MX2010001094A MX2010001094A MX 2010001094 A MX2010001094 A MX 2010001094A MX 2010001094 A MX2010001094 A MX 2010001094A MX 2010001094 A MX2010001094 A MX 2010001094A MX 2010001094 A MX2010001094 A MX 2010001094A
Authority
MX
Mexico
Prior art keywords
trazodone
hydrochloride
purified form
preparing
aqueous phase
Prior art date
Application number
MX2010001094A
Other languages
English (en)
Inventor
Giuseppe Biondi
Marcello Marchetti
Tommaso Iacongeli
Giovanni Battista Ciottoli
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39064326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010001094(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acraf filed Critical Acraf
Publication of MX2010001094A publication Critical patent/MX2010001094A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles

Abstract

Un proceso de producción de trazodona o hidrocloruro de trazodona que comprende las etapas de: (a) preparar una fase orgánica que comprende trazodona en al menos un solvente orgánico; (b) preparar una fase acuosa que comprende al menos un compuesto básico; (c) mezclar la fase acuosa con una fase orgánica; (d) calentar a una temperatura de al menos 40ºC por al menos 30 minutos; (e) recuperar la trazodona; y opcionalmente, (f) tratar la trazodona con ácido hidroclórico para obtener hidrocloruro de trazodona. Trazodona y hidrocloruro de trazodona que comprende al menos 15 ppm de sustancias de alquilo, y composición farmacéutica que comprende hidrocloruro de trazodona.
MX2010001094A 2007-08-03 2008-07-23 Trazodona y hidrocloruro de trazodona en forma purificada. MX2010001094A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001603A ITMI20071603A1 (it) 2007-08-03 2007-08-03 Trazodone e trazodone cloridrato in forma purificata
US97653507P 2007-10-01 2007-10-01
PCT/EP2008/059640 WO2009019133A1 (en) 2007-08-03 2008-07-23 Trazodone and trazodone hydrochloride in purified form

Publications (1)

Publication Number Publication Date
MX2010001094A true MX2010001094A (es) 2010-03-01

Family

ID=39064326

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001094A MX2010001094A (es) 2007-08-03 2008-07-23 Trazodona y hidrocloruro de trazodona en forma purificada.

Country Status (23)

Country Link
US (19) US8133893B2 (es)
EP (1) EP2178850B1 (es)
JP (3) JP5635401B2 (es)
KR (2) KR101505522B1 (es)
CN (1) CN101772490B (es)
AR (1) AR067773A1 (es)
BR (1) BRPI0814448B8 (es)
CA (1) CA2693095C (es)
CY (1) CY1115666T1 (es)
DK (1) DK2178850T3 (es)
EA (1) EA017019B1 (es)
ES (1) ES2517871T3 (es)
GE (2) GEP20135915B (es)
HK (1) HK1139405A1 (es)
HR (1) HRP20140978T1 (es)
IL (2) IL203294A (es)
IT (1) ITMI20071603A1 (es)
MX (1) MX2010001094A (es)
PL (1) PL2178850T3 (es)
PT (1) PT2178850E (es)
SI (1) SI2178850T1 (es)
UA (1) UA103597C2 (es)
WO (1) WO2009019133A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20071573A1 (it) 2007-07-31 2009-02-01 Acraf Composizione farmaceutica liquida stabile a base di trazodone
ITMI20071603A1 (it) * 2007-08-03 2009-02-04 Acraf Trazodone e trazodone cloridrato in forma purificata
WO2012072665A1 (en) 2010-11-30 2012-06-07 Pharmaneuroboost N.V. Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
CN103853790B (zh) * 2012-12-06 2016-04-06 腾讯科技（深圳）有限公司 移动终端浏览器的上传信息处理方法及装置
EP3097099A4 (en) * 2014-01-21 2017-08-23 Piramal Enterprises Limited An improved process for the preparation of trazodone and hydrochloride salt thereof
CN105777745A (zh) * 2016-03-29 2016-07-20 深圳市泛谷药业股份有限公司 一种盐酸曲唑酮的制备方法
PT3749668T (pt) 2018-02-07 2022-06-02 Aziende Chimiche Riunite Angelini Francesco A C R Processo contínuo para a preparação de trazodona
RU2706700C1 (ru) 2019-09-24 2019-11-20 Общество с ограниченной ответственностью "Научно-производственная компания "СКиФФ" Фармацевтическая композиция для коррекции поведения кошек и собак в стрессовых ситуациях

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR8135E (es)
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
GB1117068A (en) * 1965-12-15 1968-06-12 Acraf S-triazole-[4,3-a]-pyridine derivatives and processes for their preparation
FR8135M (es) * 1968-12-31 1970-08-10
IT1047702B (it) * 1975-07-24 1980-10-20 Acraf Nuova sintesi degli psicofarmaci denominati trazodone ed eteroperidone
US4465683A (en) * 1979-09-14 1984-08-14 Mead Johnson & Company Anti-psychotic agents
US4252806A (en) * 1979-09-24 1981-02-24 Mead Johnson & Company Triazoloquinolones
US4254124A (en) * 1979-09-24 1981-03-03 Mead Johnson & Company Antidepressant agent
IT1211095B (it) * 1981-08-17 1989-09-29 Roma Aziende Chimiche Riunite Impiego del trazodone nel trattamento delle ulcere gastroduodenali.
IT1233412B (it) * 1987-12-02 1992-03-30 Acraf Uso del trazodone
IT1314283B1 (it) * 1999-12-16 2002-12-06 Acraf Trazodone cloridrato ed un procedimento per prepararlo.
AU2004230915B2 (en) * 2003-04-08 2008-08-07 Algorx Pharmaceuticals, Inc. Preparation and purification of synthetic capsaicin
WO2007048219A2 (en) * 2005-09-09 2007-05-03 Labopharm Inc. Sustained drug release composition
ITMI20071573A1 (it) 2007-07-31 2009-02-01 Acraf Composizione farmaceutica liquida stabile a base di trazodone
ITMI20071603A1 (it) * 2007-08-03 2009-02-04 Acraf Trazodone e trazodone cloridrato in forma purificata

Also Published As

Publication number Publication date
HK1139405A1 (en) 2010-09-17
CN101772490B (zh) 2013-11-06
IL225873A (en) 2016-10-31
US20200038396A1 (en) 2020-02-06
AU2008285779A1 (en) 2009-02-12
EA017019B1 (ru) 2012-09-28
US20160113926A1 (en) 2016-04-28
UA103597C2 (en) 2013-11-11
KR20140133901A (ko) 2014-11-20
PT2178850E (pt) 2014-10-07
US8314236B2 (en) 2012-11-20
ITMI20071603A1 (it) 2009-02-04
SI2178850T1 (sl) 2014-12-31
EP2178850A1 (en) 2010-04-28
CN101772490A (zh) 2010-07-07
IL225873A0 (en) 2013-06-27
CY1115666T1 (el) 2017-01-25
PL2178850T3 (pl) 2015-03-31
JP5635401B2 (ja) 2014-12-03
US20240139179A1 (en) 2024-05-02
US20140057922A1 (en) 2014-02-27
ES2517871T3 (es) 2014-11-04
JP2010535170A (ja) 2010-11-18
US20170128442A1 (en) 2017-05-11
JP6513911B2 (ja) 2019-05-15
JP2017141246A (ja) 2017-08-17
US20160324853A1 (en) 2016-11-10
US20130012520A1 (en) 2013-01-10
US20100056539A1 (en) 2010-03-04
AR067773A1 (es) 2009-10-21
JP2014221788A (ja) 2014-11-27
US20210052577A1 (en) 2021-02-25
US20140296250A1 (en) 2014-10-02
DK2178850T3 (en) 2014-11-17
EP2178850B1 (en) 2014-09-03
BRPI0814448B1 (pt) 2019-04-02
US8133893B2 (en) 2012-03-13
BRPI0814448B8 (pt) 2021-05-25
US20190231774A1 (en) 2019-08-01
US20170333425A1 (en) 2017-11-23
KR20100046245A (ko) 2010-05-06
KR101505522B1 (ko) 2015-03-30
US20180161323A1 (en) 2018-06-14
WO2009019133A1 (en) 2009-02-12
CA2693095A1 (en) 2009-02-12
GEP20135926B (en) 2013-10-10
GEP20135915B (en) 2013-08-26
BRPI0814448A2 (pt) 2016-07-26
EA201070228A1 (ru) 2010-06-30
US20150297589A1 (en) 2015-10-22
HRP20140978T1 (hr) 2014-12-05
US20130203771A1 (en) 2013-08-08
CA2693095C (en) 2015-11-24
US20120142699A1 (en) 2012-06-07
US20200253965A1 (en) 2020-08-13
US20150105402A1 (en) 2015-04-16
US20180353503A1 (en) 2018-12-13
IL203294A (en) 2013-05-30

Similar Documents

Publication Publication Date Title
MX2010001094A (es) Trazodona y hidrocloruro de trazodona en forma purificada.
AR067775A1 (es) (2s,3r)-n-(2-((3- piridinil) metil)-1- azabiciclo (2.2.2= oct-3-il) benzofuran -2- carboxamida, formas de sales y metodos de uso
WO2006132914A3 (en) Cyclobutyl amine derivatives
MX2010006893A (es) Derivados de benzotiazol y benzoxazol y metodos de uso.
WO2007106469A3 (en) Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
NO20090173L (no) Kondensert spiroketalderivat og anvendelse derav som legemiddel for a behandle diabetes
EP2361909A4 (en) 1,3,5-TRIAZINE DERIVATIVE PRODUCTION METHOD AND ORGANIC ELECTROLUMINESCENT ELEMENT THEREWITH
MY148258A (en) Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments
MX2011005934A (es) Compuestos organicos.
EP2351750A4 (en) 1,3,5-TRIAZINE DERIVATIVE, METHOD OF MANUFACTURING THEREOF, AND THIS COMPOSITION OF AN INTEGRATED ORGANIC ELECTROLUMINESCENE ELEMENT
JO2734B1 (en) Organic compounds
TW200637863A (en) Organic compounds
WO2008084223A3 (en) Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors
BR112013022779A2 (pt) composto, composição estável, processo para preparar uma composição estável, forma amorfa estável, método para o tratamento ou a prevenção de uma doença ou condição, uso de uma forma amorfa estável, composiçao farmacêutica ou veterinária, produto, e, kit
WO2007034279A3 (en) C3a antagonists and pharmaceutical compositions thereof
GEP20115342B (en) New diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them
WO2009130604A3 (en) Solid state forms of deferasirox salts and process for the preparation thereof
SI2234979T1 (sl) 5-((3,3,3-trifluoro-2-hidroksi-1-arilpropil)amino)-1H-kinolin-2-oni, postopek njihove proizvodnje in njihova uporaba kot protivnetna sredstva
WO2010067078A8 (en) 3,6-disubstituted xanthylium salts
TW200745098A (en) Benzothiazole cyclobutyl amine derivatives
WO2007150010A3 (en) Cyclopropyl amine derivatives as histamin h3 receptor modulators
WO2010072770A3 (en) Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
WO2011009532A3 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-derivate, verfahren zu deren herstellung und deren verwendung zur behandlung von krankheiten
MX337682B (es) Metodo para fabricar derivados de almidon de hidroxietilo.
ATE500226T1 (de) Aripiprazolhemifumarat und verfahren zu dessen herstellung

Legal Events

Date Code Title Description
FG Grant or registration